ArticleJournal of thyroid research2014

Antitumor activity of lenvatinib (e7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models.

Osamu Tohyama et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.